EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Rosuvastatin Ameliorates the Initiation and Progression of Lung Adenocarcinoma via Facilitating PLK1 Inhibition

Jie Yin, Jianjie Zhu, Yinhua Gong, Wenting Wu, Xinyu Zhang, Chang Li, Yang Yang, Yili Chen, Jianjun Li, Lei Gu, Jian-An Huang, Zeyi Liu and 2 more

Frontiers in Bioscience-Landmark · 2026-04-24 · 31 (4)

DOI: 10.31083/fbl49156 ↗

At a glance

Journal article in Frontiers in Bioscience-Landmark, published online on 2026-04-24. Written by Jie Yin and 13 co-authors. Institution: Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, 215006 Suzhou, Jiangsu, China. Major MEDLINE topics: Protein Serine-Threonine Kinases, Cell Cycle Proteins, Lung Neoplasms, Proto-Oncogene Proteins. 44 references. The full text is freely available (open access, CC BY 4.0). Funded by: Science and Technology Plan Project of Suzhou, Jiangsu Provincial Medical Key Discipline.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Lung cancer remains a major global public health challenge, with lung adenocarcinoma being the most prevalent histologic subtype. Rosuvastatin, a widely used lipid-lowering agent, has recently attracted attention for its potential antitumor properties. This study investigates the underlying mechanisms and therapeutic potential of rosuvastatin in lung cancer.

Methods

The effects of rosuvastatin were evaluated in lung adenocarcinoma cell lines using Cell Counting Kit-8 (CCK-8), 5-ethynyl-2′-deoxyuridine (EdU) incorporation, Transwell migration and invasion assays, wound-healing assays, and flow cytometry for apoptosis analysis. RNA sequencing identified cell-cycle signaling pathways as the primary targets of rosuvastatin. Analysis of survival curves and differential gene expression between tumor and adjacent non-tumor tissues using public databases, including the Human Protein Atlas, Gene Expression Profiling Interactive Analysis (GEPIA), and Tumor Immune Estimation Resource (TIMER), suggested that polo-like kinase 1 (PLK1) may be a key target mediating the antitumor effects of rosuvastatin. Western blotting and quantitative reverse transcription polymerase chain reaction (qRT-PCR) were used to confirm the differential expression of PLK1 and related cell-cycle proteins in lung adenocarcinoma cells following treatment with different doses of rosuvastatin. Furthermore, rescue experiments with PLK1 knockdown were performed to verify its role in the mechanism of rosuvastatin. A subcutaneous mouse xenograft model was established in vivo to assess the antitumor activity of rosuvastatin via PLK1 inhibition.

Results

Rosuvastatin exerted significant antitumor effects against lung adenocarcinoma both in vitro and in vivo. Mechanistic studies indicated that its anticancer activity is mainly mediated by downregulating PLK1 expression.

Conclusions

By suppressing PLK1 expression, rosuvastatin inhibited cancer cell proliferation, migration, and invasion. These findings support the potential of rosuvastatin as a therapeutic agent for lung cancer, although further studies are needed to confirm its clinical utility.

Subjects

MeSH terms (MEDLINE)

Protein Serine-Threonine KinasesCell Cycle ProteinsLung NeoplasmsProto-Oncogene ProteinsRosuvastatin CalciumAdenocarcinoma of LungPolo-Like Kinase 1HumansAnimalsMiceCell ProliferationApoptosisCell Line, TumorGene Expression Regulation, NeoplasticXenograft Model Antitumor AssaysCell MovementMice, NudeDisease ProgressionFemale

Author keywords

apoptosiscell cyclelung adenocarcinomapolo-like kinase 1rosuvastatin

Substances

Polo-Like Kinase 1Protein Serine-Threonine KinasesCell Cycle ProteinsProto-Oncogene ProteinsRosuvastatin Calcium

Authors and institutions

  • Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, 215006 Suzhou, Jiangsu, China.
  • Institute of Respiratory Diseases, Soochow University, 215006 Suzhou, Jiangsu, China.
  • Suzhou Key Laboratory for Respiratory Diseases, 215006 Suzhou, Jiangsu, China.
  • Department of Cancer Diagnosis and Treatment Center, Affiliated Hospital of Jiangnan University, 214000 Wuxi, Jiangsu, China.
  • Department of Pharmacy, The First Affiliated Hospital of Soochow University, 215006 Suzhou, Jiangsu, China.

Funding

  • Science and Technology Plan Project of Suzhou
  • Jiangsu Provincial Medical Key Discipline

Cite

APA

Yin, J., Zhu, J., Gong, Y., Wu, W., Zhang, X., Li, C., Yang, Y., Chen, Y., Li, J., Gu, L., Huang, J. A., Liu, Z., Shen, D., & Zeng, Y. (2026). Rosuvastatin Ameliorates the Initiation and Progression of Lung Adenocarcinoma via Facilitating PLK1 Inhibition. Frontiers in Bioscience-Landmark, 31(4). https://doi.org/10.31083/fbl49156

Vancouver

Yin J, Zhu J, Gong Y, Wu W, Zhang X, Li C, et al. Rosuvastatin Ameliorates the Initiation and Progression of Lung Adenocarcinoma via Facilitating PLK1 Inhibition. Frontiers in Bioscience-Landmark. 2026;31(4). doi:10.31083/fbl49156

BibTeX
@article{Yin2026,
  author = {Yin, Jie and Zhu, Jianjie and Gong, Yinhua and Wu, Wenting and Zhang, Xinyu and Li, Chang and Yang, Yang and Chen, Yili and Li, Jianjun and Gu, Lei and Huang, Jian-An and Liu, Zeyi and Shen, Dan and Zeng, Yuanyuan},
  title = {Rosuvastatin Ameliorates the Initiation and Progression of Lung Adenocarcinoma via Facilitating PLK1 Inhibition},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2026},
  volume = {31},
  number = {4},
  doi = {10.31083/fbl49156}
}
Start for free →